3P Biopharmaceuticals and Invizius hope for reducing the cardiovascular complications associated with dialysis
Biotech companies Invizius and 3P Biopharmaceuticals collaborate on an innovative technology for patients undergoing hemodialysis and suffering from cardiovascular disease
Biotech companies Invizius and 3P Biopharmaceuticals collaborate on an innovative technology for patients undergoing hemodialysis and suffering from cardiovascular disease.
Invizius, a Scottish biotech company and 3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, have initiated a collaboration on an innovative treatment for reducing the cardiovascular complications with dialysis treatments.
Invizius and 3P Biopharmaceuticals began their partnership earlier this year when 3P Biopharmaceuticals was selected to be responsible for cGMP manufacturing in preparation for First-in-Human trials.
Currently, life expectancy of patients on dialysis is just one-third of normal, and half of these patients die from cardiovascular complications. The immune systems of these patients see the dialysis filter as a foreign body, creating inflammation that damages the cardiovascular system over time. Recent research reveals that patients with a higher immune response to dialysis are at higher risk of cardiovascular complications.
Invizius’s innovative H-Guard® product is a powerful anti-inflammatory that can be used to coat the filter surface to ‘hide’ it and prevent an immune response, potentially reducing cardiovascular damage and improving patients’ quality of life.
As 3P Biopharmaceuticals CEO Dámaso Molero explains: “This pioneering project offers an extraordinary hope for improving the lives of dialysis patients affected by treatment-driven complications. Therefore, we are delighted to collaborate with Invizius on such a stimulating project.”
Richard Boyd, CEO at Invizius, added: “H-Guard may represent the greatest advance in dialysis medicine in the last 25 years, a period in which there has been no significant innovation for patients, and clinical outcomes have languished and remain among the worst in modern medicine. We are delighted to be working with 3P Biopharmaceuticals to bring this pioneering treatment to the clinic.”
The technology also has potential for use with devices such as heart and lung machines, stents and grafts, or in organ transplants and cell therapies. Invizius has won awards including OBN Best Innovative Medtech and was named as one of the Fierce 15 Medtech companies to watch.
With this partnership, 3P Biopharmaceuticals confirms its capability to carry out processes and manufacture molecules developed within diverse therapeutic applications.
